Peta-base sequencing, advanced informatics and regulatory preparation; for immuno-oncology clinical trials & other applications.

Menlo Park, CA – Personalis, Inc., a precision medicine company focused on genomics solutions for immuno-oncology, targeted therapy, and genetic disease, today announced steps to increase the scale of its operations in 2017. These plans include three main elements:

Sequencing scale: Personalis is taking delivery of an Illumina HiSeq X Five System and expects it to be fully operational before the start of 2017. With Personalis’ other sequencing instruments, this will bring the company’s sequencing capacity to over one peta-base (1,000 trillion bases) in 2017. Combined with the company’s laboratory robotics and computing infrastructure, these systems will be capable of processing tens of thousands of samples in the year, and identifying tens of billions of genetic variants.

Advanced informatics for scaling and managing clinical trial complexity: Personalis h